The verification arrives as the global ashwagandha market faces increasing scrutiny over sourcing and adulteration. According to Mordor Intelligence, the sector is expected to climb from $0.76 billion in 2025 to $1.18 billion by 2030, driven by the rise of functional foods, gummies, and beverages. By standardizing Zenroot to 1.5% withanolides and utilizing USP-accessible testing methods, OmniActive aims to provide supply chain transparency that helps brands navigate these evolving quality standards.
In section Releases
OmniActive Secures USP Verification for Zenroot Ashwagandha
OmniActive Health Technologies has earned U.S. Pharmacopeia (USP) verification for Zenroot, its root-only ashwagandha extract. The certification marks a shift in the supplement industry as manufacturers prioritize independent quality assurance for botanicals, specifically targeting the demand for standardized ingredients that remain effective at a low daily dose of 125 mg.
Beyond the USP certification, the extract is supported by clinical data focused on bioavailability and efficacy. Recent research indicates that a 125 mg daily dose can assist in managing occasional stress and anxiety while supporting sleep quality. This low-dose profile is designed to solve common formulation hurdles, allowing manufacturers to integrate the botanical into diverse formats like effervescent tablets and ready-to-mix drinks without compromising on ingredient consistency.
Comments (0)
No comments yet. Be the first!